Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Childhood interstitial and diffuse lung diseases (chILD) are a heterogeneous and diverse group of rare lung disorders presenting in childhood. Unfortunately, there are few therapies and poor understanding of the natural history for most disorders. Patients encounter high morbidity and mortality. Through the establishment of national research networks and registries such as chILD EU in the European Union, chILD Research Network in the USA and the chILDRANZ: children’s interstitial lung disease research in Australia and New Zealand, progress has begun to better understand patients with chILD. The chILD EU group published two landmark manuscripts in Thorax demonstrating the value of these registries to further advance the care of these patients through evidence-based studies.
Defining acute exacerbations (AEs) and understanding their clinical impact and outcome is essential to moving chILD research forward. Seidl et al in their manuscript ‘Acute Exacerbations in Children’s Interstitial Lung Disease-A chILD-EU Cohort Study’1 provides a definition for chILD AEs that can be used as standardised criteria in future …
Contributors AC and RD equally produced the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests RD is a consultant for Boehringer Ingelheim Inc for Pediatric Interstitial Lung Disease. She is the International Coordinating Investigator for a pediatric interstitial lung disease clinical trial with this company.
Provenance and peer review Commissioned; externally peer reviewed.